PODD (Insulet) Net Margin % : 16.85% (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Insulet Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Insulet's Net Income for the three months ended in Dec. 2024 was $101 Mil. Insulet's Revenue for the three months ended in Dec. 2024 was $598 Mil. Therefore, Insulet's net margin for the quarter that ended in Dec. 2024 was 16.85%.

The historical rank and industry rank for Insulet's Net Margin % or its related term are showing as below:

PODD' s Net Margin % Range Over the Past 10 Years
Min: -27.86 Med: 0.67 Max: 20.19
Current: 20.19

PODD's Net Margin % is ranked better than
89.2% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: 0.52 vs PODD: 20.19

Insulet Net Margin % Historical Data

The historical data trend for Insulet's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Net Margin % Chart

Insulet Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Margin %

Get a 7-Day Free Trial

0.75

1.53

0.35

12.16

20.19

Insulet Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Margin %	Get a 7-Day Free Trial															20.26	11.66	38.61	14.25	16.85

Competitive Comparison of Insulet's Net Margin %

For the Medical Devices subindustry, Insulet's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insulet's Net Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Net Margin % distribution charts can be found below:

* The bar in red indicates where Insulet's Net Margin % falls into.

Save Embed

;

Save Embed

;

Insulet Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Insulet's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	418.3	/	2071.6
	=	20.19 %

Insulet's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	100.7	/	597.5
	=	16.85 %

Insulet (NAS:PODD) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Insulet Net Margin % Related Terms

Thank you for viewing the detailed overview of Insulet's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Insulet Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

GOV:Germany GOV:Germany

Address

100 Nagog Park, Acton, MA, USA, 01720

Website

https://www.insulet.com

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

Executives

Eric Benjamin	officer: SVP, R&D, New Prod Dev. & Comm	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DR, SUITE 200, BILLERICA MA 01821
Lauren Budden	officer: VP, CAO and Controller	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Luciana Borio	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Mark N Field	officer: SVP & Chief Technology Officer	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Prem Singh	officer: SVP, Global Operations	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Shacey Petrovic	officer: CCO	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
James Hollingshead	director	C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan	officer: EVP, CFO	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea	officer: SVP, Chief HR Officer	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue	director	22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin	officer: SVP, Reg, Quality & Compliance	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche	officer: SVP, Global Manufacturing	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bret Christensen	officer: SVP and CCO	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821